Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-Label, Randomized, Phase II Study of Lenvatinib Plus Pembrolizumab With or Without Branched-Chain Amino Acids in Unresectable Hepatocellular Carcinoma
Conditions
Interventions
Lenvatinib
Pembrolizumab
+1 more
Start Date
March 1, 2026
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2028
Last Updated
February 17, 2026
NCT07285850
NCT07106827
NCT06999837
NCT07141056
NCT07132515
NCT06999707
Lead Sponsor
Fudan University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions